{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-038902","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.427614+00:00","generated_at":"2026-06-04T04:51:03.478990+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Surrozen reports Phase 1a SZN-043 data: safe, target engagement, liver function effects; Phase 1b starts","bullets":["Phase 1a enrolled 48 subjects (40 healthy, 8 cirrhotic); doses 0.5-3 mg/kg IV; no serious adverse events.","Demonstrated target engagement via transient ALP increases and Wnt pathway activation by methacetin breath test.","In cirrhotic patients, dose-dependent pharmacodynamic effect and improvement in liver function via HepQuant test observed.","Initiating Phase 1b proof-of-concept trial in severe alcohol-associated hepatitis; data expected first half 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-038902","json":"https://secwatch.observer/filing/0000950170-24-038902.json","markdown":"https://secwatch.observer/filing/0000950170-24-038902.md","text":"https://secwatch.observer/filing/0000950170-24-038902.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000095017024038902/0000950170-24-038902-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000095017024038902/srzn-20240401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:51:03.478990+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}